Dyslipidemia complicated insulin resistance
Conditions
Interventions
Take Ezetimib:10mg/day for 12 months.
Sponsors
The Department of Diabetes, Endocrinology and Metabolism, Tokyo Medical University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)LDL-C>=120mg/dL 2)Patients not change drug therapy for anti-dyslipidemic and/or anti-diabetic agent within 12weeks of the study entry. 3)HOMA-IR>=2.5 or BMI>=25
Exclusion criteria
Exclusion criteria: 1)HbA1c>=8% 2)Patients with anamnesis for anaphylaxis of ezetimibe tablets 3)Complicated with Severe renal and/or hepatic disease 4)Having anamnesis of myocardial infarction, angina and/or stroke 5)Patients with secondary hyperlipidemia or drug-associated hyperlipidemia 6)Patients who are pregnant or lactating women and women suspected of being pregnant 7)Patients of Familial hyperlipidemia 8)Other patients deemed not appropriate for study entry by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)Flow Mediated Dilation test 2)Volume of visceral fat and fatty liver) 3)Improvement ratio of Cholesterol Absorption and Synthesis Markers 4)Improvement ratio of Oxidized low density lipoprotein and Atherogenic lipoprotein level 3) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Improvement ratio of glucose metabolism makers 2)Improvement of inflammatory makers and Oxidation makers | — |
Countries
Japan
Contacts
Public ContactMiwa Takashi
Tokyo Medical University The Department of Diabetes, Endocrinology and Metabolism
Outcome results
None listed